RT @Cardio_delaGuia: Hepatopatía #edoxaban y #warfarina • La existencia de enfermedad hepática NO altera la eficacia y seguridad de edoxab…
RT @Cardio_delaGuia: Hepatopatía #edoxaban y #warfarina • La existencia de enfermedad hepática NO altera la eficacia y seguridad de edoxab…
RT @Cardio_delaGuia: Hepatopatía #edoxaban y #warfarina • La existencia de enfermedad hepática NO altera la eficacia y seguridad de edoxab…
RT @Cardio_delaGuia: Hepatopatía #edoxaban y #warfarina • La existencia de enfermedad hepática NO altera la eficacia y seguridad de edoxab…
RT @Cardio_delaGuia: Hepatopatía #edoxaban y #warfarina • La existencia de enfermedad hepática NO altera la eficacia y seguridad de edoxab…
RT @Cardio_delaGuia: Hepatopatía #edoxaban y #warfarina • La existencia de enfermedad hepática NO altera la eficacia y seguridad de edoxab…
RT @Cardio_delaGuia: Hepatopatía #edoxaban y #warfarina • La existencia de enfermedad hepática NO altera la eficacia y seguridad de edoxab…
Hepatopatía #edoxaban y #warfarina • La existencia de enfermedad hepática NO altera la eficacia y seguridad de edoxabán en comparación con warfarina. • Los eventos adversos hepáticos fueron SIMILARES entre edoxabán y warfarina. #ACOD #cardiotwitter ✔️h
RT @Cardio_delaGuia: Hepatopatía y #edoxaban 1️⃣ La existencia de enfermedad hepática no altera la eficacia y seguridad de edoxabán en com…
RT @Cardio_delaGuia: Hepatopatía y #edoxaban 1️⃣ La existencia de enfermedad hepática no altera la eficacia y seguridad de edoxabán en com…
Hepatopatía y #edoxaban 1️⃣ La existencia de enfermedad hepática no altera la eficacia y seguridad de edoxabán en comparación con warfarina. 2️⃣ Los eventos adversos hepáticos fueron similares entre edoxabán y warfarina. #ACOD #cardiotwitter 🔗https://t
一応前回はこんな報告があったのをツイートしてました。 https://t.co/e6gyGJXzeR
RT @pinacol: 肝疾患をかかえる心房細動患者へのエドキサバンの投与は、ワルファリンと比較して、脳卒中/全身性塞栓症イベントおよび大出血のハザード比は同様であった(エドキサバンのPK/PDは肝疾患の有無による差はなかった)。 https://t.co/UxkXgdS8sN
肝疾患をかかえる心房細動患者へのエドキサバンの投与は、ワルファリンと比較して、脳卒中/全身性塞栓症イベントおよび大出血のハザード比は同様であった(エドキサバンのPK/PDは肝疾患の有無による差はなかった)。 https://t.co/UxkXgdS8sN
RT @JACCJournals: #JACC study evaluates the pharmacokinetics, pharmacodynamics, clinical efficacy and safety of edoxaban vs. warfarin in pa…
Compared to those without liver dysfunction, edoxaban for NVAF in liver dysfunction is associated with no difference in stroke or systemic embolism but does confer a greater bleeding risk per an analysis of ENGAGE-AF published in @JACCJournals today. https
RT @JACCJournals: #JACC study evaluates the pharmacokinetics, pharmacodynamics, clinical efficacy and safety of edoxaban vs. warfarin in pa…
RT @JACCJournals: #JACC study evaluates the pharmacokinetics, pharmacodynamics, clinical efficacy and safety of edoxaban vs. warfarin in pa…
RT @JACCJournals: #JACC study evaluates the pharmacokinetics, pharmacodynamics, clinical efficacy and safety of edoxaban vs. warfarin in pa…
RT @JACCJournals: #JACC study evaluates the pharmacokinetics, pharmacodynamics, clinical efficacy and safety of edoxaban vs. warfarin in pa…
RT @JACCJournals: #JACC study evaluates the pharmacokinetics, pharmacodynamics, clinical efficacy and safety of edoxaban vs. warfarin in pa…
RT @JACCJournals: #JACC study evaluates the pharmacokinetics, pharmacodynamics, clinical efficacy and safety of edoxaban vs. warfarin in pa…
RT @JACCJournals: #JACC study evaluates the pharmacokinetics, pharmacodynamics, clinical efficacy and safety of edoxaban vs. warfarin in pa…
RT @JACCJournals: #JACC study evaluates the pharmacokinetics, pharmacodynamics, clinical efficacy and safety of edoxaban vs. warfarin in pa…
RT @PhsmSam: Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease | JACC: Journal of the American Col…
RT @JACCJournals: #JACC study evaluates the pharmacokinetics, pharmacodynamics, clinical efficacy and safety of edoxaban vs. warfarin in pa…
Are DOACs for #afib safe in liver disease? ENGAGE AF-TIMI 48 (https://t.co/JQS0FHlH10) provides new insight! Synopsis: https://t.co/0oBNKwSQa6 @JACCJournals #atrialfibrillaton
RT @JACCJournals: #JACC study evaluates the pharmacokinetics, pharmacodynamics, clinical efficacy and safety of edoxaban vs. warfarin in pa…
RT @JACCJournals: #JACC study evaluates the pharmacokinetics, pharmacodynamics, clinical efficacy and safety of edoxaban vs. warfarin in pa…
RT @JACCJournals: #JACC study evaluates the pharmacokinetics, pharmacodynamics, clinical efficacy and safety of edoxaban vs. warfarin in pa…
#JACC study evaluates the pharmacokinetics, pharmacodynamics, clinical efficacy and safety of edoxaban vs. warfarin in patients with #AFib and liver disease. https://t.co/GPM4Sr6o76 https://t.co/V3x4Pq6PUN
RT @AqamarMD: In @JACCJournals , we show consistent benefit of edoxaban in pts w/ & w/o liver dz. Edoxaban Vs Warfarin in Pts w/AF & Hx of…
RT @PhsmSam: Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease | JACC: Journal of the American Col…
RT @AqamarMD: In @JACCJournals , we show consistent benefit of edoxaban in pts w/ & w/o liver dz. Edoxaban Vs Warfarin in Pts w/AF & Hx of…
Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease | JACC: Journal of the American College of Cardiology https://t.co/i5nveHW4Do
RT @AqamarMD: In @JACCJournals , we show consistent benefit of edoxaban in pts w/ & w/o liver dz. Edoxaban Vs Warfarin in Pts w/AF & Hx of…
RT @AqamarMD: In @JACCJournals , we show consistent benefit of edoxaban in pts w/ & w/o liver dz. Edoxaban Vs Warfarin in Pts w/AF & Hx of…
RT @AqamarMD: In @JACCJournals , we show consistent benefit of edoxaban in pts w/ & w/o liver dz. Edoxaban Vs Warfarin in Pts w/AF & Hx of…
RT @AqamarMD: In @JACCJournals , we show consistent benefit of edoxaban in pts w/ & w/o liver dz. Edoxaban Vs Warfarin in Pts w/AF & Hx of…
RT @AqamarMD: In @JACCJournals , we show consistent benefit of edoxaban in pts w/ & w/o liver dz. Edoxaban Vs Warfarin in Pts w/AF & Hx of…
RT @AqamarMD: In @JACCJournals , we show consistent benefit of edoxaban in pts w/ & w/o liver dz. Edoxaban Vs Warfarin in Pts w/AF & Hx of…
In @JACCJournals , we show consistent benefit of edoxaban in pts w/ & w/o liver dz. Edoxaban Vs Warfarin in Pts w/AF & Hx of Liver Dz https://t.co/K1V90PUWND @eantman #EugeneBraunwald @rgiugliano @TIMIStudyGroup @HarvardChanSPH #CardioHepatology @n
RT @JACCJournals: Liver disease did not alter the relative efficacy and safety of edoxaban compared to warfarin in patients with #AFib. htt…
RT @JACCJournals: Liver disease did not alter the relative efficacy and safety of edoxaban compared to warfarin in patients with #AFib. htt…
RT @JACCJournals: Liver disease did not alter the relative efficacy and safety of edoxaban compared to warfarin in patients with #AFib. htt…
RT @JACCJournals: Liver disease did not alter the relative efficacy and safety of edoxaban compared to warfarin in patients with #AFib. htt…
RT @JACCJournals: Liver disease did not alter the relative efficacy and safety of edoxaban compared to warfarin in patients with #AFib. htt…
RT @JACCJournals: Liver disease did not alter the relative efficacy and safety of edoxaban compared to warfarin in patients with #AFib. htt…
RT @JACCJournals: Liver disease did not alter the relative efficacy and safety of edoxaban compared to warfarin in patients with #AFib. htt…
RT @JACCJournals: Liver disease did not alter the relative efficacy and safety of edoxaban compared to warfarin in patients with #AFib. htt…
Liver disease did not alter the relative efficacy and safety of edoxaban compared to warfarin in patients with #AFib. https://t.co/IIck9DwPuu #JACC https://t.co/HnNB1snTyN
RT @Less_is_more_1: https://t.co/w0jNfna7v1 Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease #Ca…
https://t.co/w0jNfna7v1 Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease #CardioEd #cardiotwitter #cardiology #interventionalcardiology #CTO101 #CTO2019 #CTO #WarOnCalcium #IVUS #PCI #CHIP
RT @naderjo: No difference re bleeding and/or embolic events for Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History…
No difference re bleeding and/or embolic events for Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease https://t.co/7QiWzLciPF #Cardiology #CardioTwitter
NOACs are as safe and efficacious as Warfarin in #Afib https://t.co/MaFzbKzUyW